IRADIMED CORP
For the period ended Sep 30, 2026. Filed Oct 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangement Changes
On August 7, 2026, Roger Susi, the Company's President, Chief Executive Officer, and Chairman of the Board, adopted a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a "10b5-1 trading plan") under the Exchange Act. This 10b5-1 trading plan provides for the potential sale of up to 50,000 shares of common stock. Pursuant to its terms, this 10b5-1 trading plan is expected to remain in place until the earlier of (i)February 10, 2027 and (ii) the date on which all transactions under such plan are completed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.